Amneal Pharmaceuticals Inc (NYSE:AMRX) – Research analysts at Svb Leerink cut their FY2019 EPS estimates for shares of Amneal Pharmaceuticals in a note issued to investors on Thursday, April 18th, Zacks Investment Research reports. Svb Leerink analyst A. Fadia now forecasts that the company will post earnings of $0.95 per share for the year, down from their previous forecast of $0.97. Svb Leerink currently has a “Market Perform” rating and a $12.00 target price on the stock. Svb Leerink also issued estimates for Amneal Pharmaceuticals’ Q4 2019 earnings at $0.26 EPS and FY2023 earnings at $1.67 EPS.
A number of other research firms also recently issued reports on AMRX. SunTrust Banks began coverage on shares of Amneal Pharmaceuticals in a report on Tuesday, March 19th. They set a “buy” rating and a $16.00 price objective on the stock. ValuEngine downgraded shares of Amneal Pharmaceuticals from a “sell” rating to a “strong sell” rating in a report on Friday, April 5th. Zacks Investment Research raised shares of Amneal Pharmaceuticals from a “strong sell” rating to a “hold” rating in a report on Wednesday. Cantor Fitzgerald reissued a “buy” rating and issued a $35.00 price target on shares of Amneal Pharmaceuticals in a report on Thursday, February 28th. Finally, Leerink Swann downgraded shares of Amneal Pharmaceuticals to a “market perform” rating in a report on Friday, March 8th. One analyst has rated the stock with a sell rating, eight have issued a hold rating and four have given a buy rating to the stock. Amneal Pharmaceuticals has an average rating of “Hold” and an average target price of $20.10.
Amneal Pharmaceuticals (NYSE:AMRX) last posted its quarterly earnings data on Thursday, May 9th. The company reported $0.11 earnings per share (EPS) for the quarter, missing the Zacks’ consensus estimate of $0.18 by ($0.07). The firm had revenue of $446.00 million for the quarter, compared to analysts’ expectations of $438.18 million. Amneal Pharmaceuticals had a positive return on equity of 32.14% and a negative net margin of 3.75%. The firm’s revenue for the quarter was up 4.9% on a year-over-year basis.
In related news, Director Peter R. Terreri sold 23,345 shares of the business’s stock in a transaction dated Wednesday, March 6th. The shares were sold at an average price of $12.39, for a total value of $289,244.55. The sale was disclosed in a filing with the SEC, which can be accessed through the SEC website. Also, insider Paul Bisaro purchased 17,000 shares of the business’s stock in a transaction that occurred on Tuesday, March 12th. The stock was bought at an average cost of $11.97 per share, for a total transaction of $203,490.00. The disclosure for this purchase can be found here. 26.34% of the stock is currently owned by insiders.
Institutional investors have recently made changes to their positions in the stock. Bessemer Group Inc. bought a new stake in Amneal Pharmaceuticals in the 4th quarter valued at about $34,000. NumerixS Investment Technologies Inc raised its stake in Amneal Pharmaceuticals by 52.1% in the 1st quarter. NumerixS Investment Technologies Inc now owns 3,052 shares of the company’s stock valued at $42,000 after acquiring an additional 1,045 shares during the period. Quantamental Technologies LLC bought a new stake in Amneal Pharmaceuticals in the 4th quarter valued at about $68,000. Zurcher Kantonalbank Zurich Cantonalbank raised its stake in Amneal Pharmaceuticals by 28.3% in the 4th quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 6,700 shares of the company’s stock valued at $91,000 after acquiring an additional 1,477 shares during the period. Finally, Meeder Asset Management Inc. raised its stake in Amneal Pharmaceuticals by 785.6% in the 1st quarter. Meeder Asset Management Inc. now owns 11,664 shares of the company’s stock valued at $166,000 after acquiring an additional 10,347 shares during the period. Institutional investors and hedge funds own 38.85% of the company’s stock.
About Amneal Pharmaceuticals
Amneal Pharmaceuticals, Inc, together with its subsidiaries, develops, licenses, manufactures, markets, and distributes generic and specialty pharmaceutical products for various dosage forms and therapeutic areas. It operates through two segments, Generics and Specialty. The Generics segment develops, manufactures, and commercializes complex oral solids, injectables, ophthalmics, liquids, topicals, softgels, inhalation products, and transdermals across a range of therapeutic categories.
Read More: What Is An Exchange-Traded Fund (ETF)?
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Amneal Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Amneal Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.